Vivani Medical Announces Private Placement Equity Financing
Key Highlights
- ➤Vivani priced 5,049,506 shares at $1.01, targeting approximately $5.1 million gross proceeds
- ➤Board members Gregg Williams and Aaron Mendelsohn purchased the private placement shares
- ➤Net proceeds expected to fund operations into the third quarter of 2027
- ➤NPM-139 Phase 2 weight-maintenance trial anticipated to begin in 2027
- ➤Five of 10 Wegovy controls reported treatment-related gastrointestinal adverse events
ALAMEDA, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced a private placement of 5,049,506 shares of its common stock at an offering price of $1.01 per share purchased by Gregg Williams, the Chairman of the Company’s board of directors, and Aaron Mendelsohn, another member of the Company’s board of directors, pursuant to a Share Purchase Agreement dated November 15, 2026. The gross proceeds to the Company from the private placement are expected to be approximately $5.1 million, before estimated offering expenses. The financing follows the Company’s November 12, 2026 announcement of positive top-line results from SLIM-1, its first-in-human Phase 1 clinical trial of NPM-139, which support advancing NPM-139 toward a Phase 2 dose-ranging weight maintenance trial anticipated to begin in 2027.
Get started
Create a free account to read the full story.
